What can we learn from a raft of early cell therapy companies with novel or intriguing approaches?
How can we use metabolic reprogramming to enhance CAR T cell therapy?
If we were to tackle CAR T cell therapy design differently, how would we go about doing it?
There are some creative and innovative new CAR T cell therapy designs being developed - what are they and where will they be tested?
Review of 12 posters that caught our attention in the ePoster Hall at ASGCT20
Will CAR-NK cells follow CAR-T cell therapies and hit prime time?
Holbrook Kohrt is a Stanford medical oncologist and clinical researcher who is leading the way in cancer immunotherapy combination strategies targeting CD137 (4-1BB).
Dr Carl June on progress of CAR T cell therapies in CLL, myeloma and solid tumours
We know that TILs can be effective in advanced melanoma, but what about common epithelial solid tumours? Can it work in these cancers too? Find out from Dr Rosenberg's latest work what's happening...
Oncolytic viruses are fast becoming a hot new area in cancer research but who are the players and where is this field going?
Editas presented some elegant work using their gene editing technology with CRISPR/Cas9 to modify T cells at ASGCT. Who would have guessed a short time afterwards Juno and Celgene would sign a 10 year collaboration?
Do you need to incorporate a suicide suicide switch into CAR T cells that allows you to turn off the response, force the T cells to self-destruct?
Data at ASGCT and ASCO highlight potential new treatments in development for multiple myeloma
Dr Tom Gajewski is working on STING agonists that may have a major role to play in cancer immunotherapy.
At the 2015 annual meeting of the American Association of Immunologists (AAI) in New Orleans, leading experts shared their insights on the “Promise of Cancer Immunotherapy."